SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

TRVI

Trevi Therapeutics Inc.
NASDAQHealth Care

Latest close: 11.88 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 15, 2026Reported sale · Form 4Michael Thomas Heffernan · $276.5KOpen the filing ↗
  2. Sep 15, 2026Reported sale · Form 4Michael Thomas Heffernan · $1.6KOpen the filing ↗
  3. Sep 15, 2026Reported sale · Form 4Michael Thomas Heffernan · $316.2KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record50121 flagged findings
Reported transactions (Form 4)80since Aug 19, 2024 · and 10 other holdings
Corporate events (8-K)28since Jul 2, 2019

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-05share offering or dilution eventrecentOpen filing ↗
    “…to which the Company agreed to issue and sell to the purchasers, in a private placement priced at-the-market under Nasdaq rules,…”
    +1 more passage from the same document
    • “…in a private placement priced at-the-market under Nasdaq rules, (i) 4,580,526 shares of the Company’s common stock at a…”
  • 2026-04-17share offering or dilution eventrecentOpen filing ↗
    “…cough in patients with non-IPF ILD, and in patients with RCC. Accordingly, we will be required to obtain further funding through…”
    +1 more passage from the same document
    • “…the period ending 60 days after the date of this prospectus supplement, or the restricted period: • offer, pledge, sell, contract…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 501)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 17, 26Form 4 ↗Insider transaction
  • Sep 15, 26Form 144 ↗Notice of proposed sale
  • Aug 6, 2610-Q ↗Quarterly report
  • Aug 6, 268-K ↗Current report · Results
  • Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 8.8% · event on Jun 30, 26 · amendment
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Jun 4, 268-K ↗Current report · Bylaws or fiscal year change · Shareholder vote results
  • May 7, 26SCHEDULE 13D/A ↗Stake with intent to influence · New Enterprise Associates 16, L.P. · 10.5% · event on May 5, 26 · amendment
  • May 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 6.3% · event on Mar 31, 26 · amendment
  • May 5, 2610-Q ↗Quarterly report
  • May 5, 268-K ↗Current report · Results
  • Apr 21, 26DEF 14A ↗Shareholder meeting and votes
  • Apr 21, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 17, 26424B5 ↗Securities offering
  • Apr 17, 268-K ↗Current report · Entered a material agreement
  • Apr 16, 26424B5 ↗Securities offering
  • Apr 10, 26PRE 14A ↗Shareholder meeting and votes
  • Mar 27, 26SCHEDULE 13G/A ↗Passive stake · amendment
  • Mar 17, 2610-K ↗Annual report
  • Mar 17, 268-K ↗Current report · Results
  • Mar 9, 268-K ↗Current report · Other events

501 filings on record, the oldest from Dec 18, 18.

Listing the 25 most recent filings of the 501 on record.

8-Ks, explained

Stress1Structure14Governance13
  • Apr 17, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2025show all 3hide
    • Dec 5, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Aug 20, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jun 17, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jun 4, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Dec 16, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Oct 1, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Structure3 material agreements entered2022show all 3hide
    • Sep 23, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • May 16, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Apr 7, 22StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Jan 14, 22StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Structure4 material agreements entered2021show all 4hide
    • Oct 19, 21StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
    • Oct 1, 21StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
    • Jul 7, 21StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Jun 21, 21StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance9 senior executive changes2019 – 2021show all 9hide
    • Apr 2, 21GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Mar 22, 21GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Sep 11, 20GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jun 30, 20GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jun 17, 20GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Feb 18, 20GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jan 6, 20GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Sep 24, 19GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jul 2, 19GovernanceA senior executive left or was appointed8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • New Enterprise Associates 16, L.P.10.5%May 5, 26SCHEDULE 13D/A ↗13 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • James N. Topper10.6%Mar 31, 25SCHEDULE 13G/A ↗14 co-filers on this document — the figure is the largest single stake, not their sum.
  • FMR LLC8.8%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Frazier Life Sciences Public Fund, L.P.7.0%Sep 30, 25SCHEDULE 13G/A ↗14 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.5.6%Sep 30, 25SCHEDULE 13G ↗
  • The Vanguard Group5.0%Dec 31, 25SCHEDULE 13G ↗
show 4 more holdershide
  • VIKING GLOBAL INVESTORS LP4.2%Sep 30, 25SCHEDULE 13G/A ↗11 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Rubric Capital Management LP2.9%Dec 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Venrock Healthcare Capital Partners II, L.P.1.4%Dec 31, 24SCHEDULE 13G/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum.
  • Rosalind Advisors, Inc.1.2%Feb 13, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 15, MICHAEL HEFFERNAN filed notice of intent to sell up to $627K. That is about 0.03% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $594K across 3 trades on Sep 15, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 15, 26Sell$276KMichael Thomas Heffernan↗
  • Sep 15, 26Sell$2KMichael Thomas Heffernan↗
  • Sep 15, 26Sell$316KMichael Thomas Heffernan↗
  • Mar 25, 25Sell$17KTHOMAS SCIASCIAChief Scientific Officer↗
  • Mar 21, 25Sell$35KJENNIFER L GOODPresident & CEO↗
  • Mar 10, 25Sell$518KFarrell SimonChief Commercial Officer↗
  • Mar 10, 25Sell$31KFarrell SimonChief Commercial Officer↗
  • Sep 9, 24Sell$6KJENNIFER L GOODPresident & CEO↗
  • Sep 6, 24Sell$13KJENNIFER L GOODPresident & CEO↗
  • Sep 5, 24Sell$125KJENNIFER L GOODPresident & CEO↗
  • Sep 4, 24Sell$33KJENNIFER L GOODPresident & CEO↗
  • Sep 3, 24Sell$12KJENNIFER L GOODPresident & CEO↗

There are 2 more transactions in this stretch.

Stock compensation, tax and giftsshow the 26 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 15, 26Compensation$56KMichael Thomas Heffernan↗
  • Sep 15, 26Compensation$70KMichael Thomas Heffernan↗
  • Dec 2, 25Compensation$2KChristopher GallettaSee Remarks↗
  • Apr 17, 25Other$2.5MCarmen Chang↗
  • Apr 17, 25Other$2.5MPaul Edward Walker↗
  • Apr 17, 25Other$2.5MMohamad Makhzoumi↗
  • Apr 17, 25Other$2.5MFOREST BASKETT↗
  • Apr 17, 25Other$2.5MAnthony A. Florence Jr.↗
  • Apr 17, 25Other$2.5MNew Enterprise Associates 16, L.P.↗
  • Apr 17, 25Other$2.5MAli Behbahani↗
  • Apr 17, 25Other$2.5MSCOTT D SANDELL↗
  • Mar 25, 25Compensation$4KTHOMAS SCIASCIAChief Scientific Officer↗
  • Mar 21, 25Compensation$8KJENNIFER L GOODPresident & CEO↗
  • Mar 10, 25Compensation$56KFarrell SimonChief Commercial Officer↗
  • Mar 10, 25Compensation$250KFarrell SimonChief Commercial Officer↗
  • Mar 10, 25Compensation$16KFarrell SimonChief Commercial Officer↗
  • Jan 8, 25Compensation$3KLisa DelfiniChief Financial Officer↗
  • Jan 7, 25Compensation$511Lisa DelfiniChief Financial Officer↗
  • Dec 13, 24Compensation$8KChristopher GallettaSee Remarks↗
  • Sep 9, 24Compensation$3KJENNIFER L GOODPresident & CEO↗
  • Sep 6, 24Compensation$6KJENNIFER L GOODPresident & CEO↗
  • Sep 5, 24Compensation$58KJENNIFER L GOODPresident & CEO↗
  • Sep 4, 24Compensation$16KJENNIFER L GOODPresident & CEO↗
  • Sep 3, 24Compensation$6KJENNIFER L GOODPresident & CEO↗
  • Aug 27, 24Compensation$7KDavid P Meeker↗
  • Aug 19, 24Compensation$24KTHOMAS SCIASCIAChief Scientific Officer↗

The full record holds 74 transactions and goes back to Feb 13, 23.

Its sector and its market

Trevi Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Trevi Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Trevi Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
501 documents on file, from Dec 18, 2018 to Sep 17, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.